3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
1320
Neoplasms
983
Carcinoma, Non-Small-Cell Lung
858
Prostatic Neoplasms
723
Colorectal Neoplasms
662
Lung Neoplasms
548
Leukemia, Myeloid, Acute
475
Neoplasm Metastasis
431
Pancreatic Neoplasms
418
Carcinoma, Hepatocellular
406
Multiple Myeloma
397
Ovarian Neoplasms
391
Stomach Neoplasms
378
Recurrence
365
Squamous Cell Carcinoma of Head and Neck
325
Melanoma
293
Brain Neoplasms
287
Uterine Cervical Neoplasms
283
Triple Negative Breast Neoplasms
271
Head and Neck Neoplasms
263
Glioblastoma
263
Precursor Cell Lymphoblastic Leukemia-Lymphoma
254
Endometrial Neoplasms
233
Lymphoma
227
Esophageal Neoplasms
222
Rectal Neoplasms
221
Sarcoma
211
Carcinoma, Renal Cell
203
Colonic Neoplasms
193
Lymphoma, Large B-Cell, Diffuse
191
Interventions
padeliporfin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Interventional
×
Transitional Cell Cancer of Renal Pelvis and Ureter
×
Clear all
NCT04620239
2026-02-04
UCM301
Steba Biotech S.A.
Phase 3
Recruiting
100 enrolled